Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.

Francisco-Javier PeñalverJosé-Antonio MárquezSoledad DuránPilar GiraldoAlejandro MartínCarlos MontalbánJuan-Manuel SanchoMaría-José RamírezMaría-José TerolFrancisco-Javier CapoteAntonio GutierrezBlanca SánchezAndrés LópezAntonio Salar-SilvestreGil Rodríguez-CaravacaMiguel CanalesMaría-Dolores Caballeronull null

Published in: Cancer medicine (2019)

ClinicalTrials.gov # NCT01133158.

Keyphrases

diffuse large b cell lymphoma
hodgkin lymphoma
chronic lymphocytic leukemia
acute myeloid leukemia
acute lymphoblastic leukemia
high dose
open label
multiple myeloma
study protocol